Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Director/PDMR Shareholding

27 Apr 2010 15:45

RNS Number : 8914K
ABCAM Plc
27 April 2010
 



 

 

Abcam plc ("Abcam" or "the Company")

 

Director Dealings

 

Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces that it was notified on 27 April 2010 that Prof. Tony Kouzarides, a non-executive director of the Company, sold 29,000 ordinary shares of 1 pence each in the Company on 27 April 2010 at a price of 1187p per ordinary share. Following this transaction Prof. Kouzarides has an interest in 85,244 ordinary shares of 1 pence each in the Company representing approximately 0.24% of the Company's issued share capital.

 

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeffrey Iliffe, Chief Financial Officer

Numis Securities

+ 44 (0) 20 7260 1000

Michael Meade / Nick Westlake, Nominated Adviser

James Black, Corporate Broking

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Stasa Filiplic

 

Notes for editors:

 

About Abcam plc

 

Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now has a rapidly growing online catalogue and as at 31 December 2009 it contained 57,960 products, most of which are antibodies, from over 250 suppliers. Abcam employs 250 staff in its four operating companies.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSZDLFLBZFXBBQ
Date   Source Headline
7th Jun 20067:00 amRNSTrading Update
9th May 20067:02 amRNSCommercial Development Appt.
27th Mar 200612:06 pmRNSDirector/PDMR Shareholding
14th Feb 20067:01 amRNSInterim Results
31st Jan 20067:01 amRNSNotification of Results
22nd Dec 20054:08 pmRNSDirectors Shareholding
3rd Nov 20057:00 amRNSFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.